Date: March 09, 2021
Time: 8:00am (PST), 11:00am (EST)
Lung cancer is one of the three most common types of cancer. Representing 85% of all lung cancers, non-small cell lung cancer has the highest cancer mortality rate worldwide. Therefore, research into possible therapeutic or preventative approaches is understandably fast and furious.
In this webinar, Dr. Telma Santos, Global Product Manager for Ultrahigh-Content Imaging at Miltenyi Biotec, will demonstrate how the MACSima™ Imaging Platform unlocks truly unprecedented insight into the spatial organization and complex functional interrelationship of cells in the tumor microenvironment.
MICS (MACSima Imaging Cyclic Staining) technology allows imaging of hundreds of markers on a single sample and multiple samples in a single experiment. See how more than 150 antibodies were used to investigate two of the most common non-small-cell lung cancers (lung adenocarcinoma and squamous-cell carcinoma) with special focus on the infiltration of immune cells into the tumor tissue. In-depth analysis by the platform’s state-of-the-art Qi Tissue software also allowed the identification of the most common cell types relevant for immuno-oncology research. In addition, data for cell numbers, structure, and spatial organization were extracted and compared throughout the tissue.
The possibility of analyzing hundreds of markers on a single sample not only facilitates the identification of basic structures, but it also enables the analysis of a plethora of proteins to advance biomarker research, drug target discovery, and deep phenotyping. Ultimately, all these approaches can help advance research towards the development of novel diagnostics and therapies.
Make no mistake: This webinar redefines what it means to draw insight from imaging experiments, so register now!
Webinars will be available for unlimited on-demand viewing after live event.